Granisetron and ondansetron for prevention of nausea and vomiting in patients undergoing modified radical mastectomy.

Department of Anesthesiology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Anaesthesia and intensive care (Impact Factor: 1.47). 12/2004; 32(6):761-4.
Source: PubMed

ABSTRACT Modified radical mastectomy is associated with a relatively high incidence of postoperative nausea and vomiting (PONV). This study was undertaken to evaluate the comparative profile and efficacy of ondansetron and granisetron to prevent PONV after modified radical mastectomy. In a randomized, double-blind, placebo-controlled trial, sixty female patients received ondansetron 4 mg, granisetron 1 mg or saline intravenously just before induction of anaesthesia (n = 20 for each group). A standardized general anaesthetic technique was employed. The incidence of PONV and adverse events were recorded for the first 24h postoperatively. The incidence of PONV was 25% with ondansetron, 20% with granisetron and 70% with saline (P < 0.05, Chi-square test with Yates' correction factor). The incidence of adverse events was comparable among the groups. Ondansetron and granisetron are both effective for reducing the incidence of PONV in female patients undergoing modified radical mastectomy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Post-anesthetic care reduces the anesthesia-related postoperative complications and mortality, shortens the length of stay at the postoperative care units and improves patient satisfaction.
    Revista Colombiana de Anestesiologia 12/2014; 380(1). DOI:10.1016/j.rca.2014.10.008
  • [Show abstract] [Hide abstract]
    ABSTRACT: Post-operative nausea and vomiting (PONV) pose unique challenges in neurosurgical patients that warrant its study separate from other surgical groups. This prospective, randomized, double-blind study was carried out to compare and to evaluate the efficacy and safety of three antiemetic combinations for PONV prophylaxis following craniotomy. A total of 75 anesthesiologist status I/II patients undergoing elective craniotomy for brain tumors were randomized into three groups, G, O and D, to receive single doses of dexamethasone 8 mg at induction with either granisetron 1 mg, ondansetron 4 mg or normal saline 2 ml at the time of dural closure respectively. Episodes of nausea, retching, vomiting and number of rescue antiemetic (RAE) were noted for 48 h post-operatively. Analysis of variance with post-hoc significance and Chi-square test with fisher exact correction were used for statistical analysis. P <0.05 was considered to be significant and P < 0.001 as highly significant. We found that the incidence and number of vomiting episodes and RAE required were significantly low in Group G and O compared with Group D; P < 0.05. However, incidence of nausea and retching were comparable among all groups. The anti-nausea and anti-retching efficacy of all the three groups was comparable. Single dose administration of granisetron 1 mg or ondansetron 4 mg at the time of dural closure with dexamethasone 8 mg provide an effective and superior prophylaxis against vomiting compared with dexamethasone alone without interfering with post-operative recovery and neurocognitive monitoring and hence important in post-operative neurosurgical care.
    11/2013; 8(1):72-77. DOI:10.4103/0259-1162.128914
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective is to evaluate the prophylactic profile, efficacy of granisetron and ondansetron to prevent postoperative nausea and vomiting (PONV) after middle ear surgery. In a randomized, double blind trial, one hundred patients undergoing middle ear surgery received either granisetron 1 mg or ondansetron 8 mg in equal volume (n = 50 for each) intravenously towards the end of surgery and before reversal of anaesthesia. A standard general anaesthetic technique was employed. Postoperatively, during the first 24 h after anaesthesia, the incidence of PONV, recovery score, time to first feeding, willingness to have the same prophylactic antiemetic drug in future and adverse events were recorded. The incidence of vomiting once (PONV score 2) was significantly less, 4% with granisetron and 22% with ondansetron (P = 0.002) respectively and the incidence of vomiting twice or more times in 30 min interval (PONV score 3) was significantly less, 8% with granisetron as compared to 34% with ondansetron (P = 0.001). The requirement of rescue antiemetic drug was significantly higher in ondansetron group, i.e. 34 vs. 8% in granisetron group (P = 0.001). The incidence of adverse events, recovery score and time to first feeding were comparable among the groups. Willingness to have the same prophylactic antiemetic drug in future was significantly high in patients receiving granisetron. Granisetron is more efficacious and desirable drug than ondansetron for reducing the incidence of PONV in patients undergoing middle ear surgery.
    Indian Journal of Otolaryngology and Head & Neck Surgery 01/2014; DOI:10.1007/s12070-011-0464-7 · 0.05 Impact Factor